MetaVia Inc.
MTVA
Classifica tra le azioni
#32908
Headquartered in Cambridge, Massachusetts, MetaVia Inc. operates as a... Headquartered in Cambridge, Massachusetts, MetaVia Inc. operates as a clinical-stage biotechnology company with a core focus on discovering and commercializing novel pharmaceutical solutions for cardiometabolic disorders. Its leading investigational drug, DA-1241, a unique G-Protein-Coupled Receptor 119 agonist, is currently undergoing Phase 2a clinical trials for metabolic dysfunction-associated steatohepatitis (MASH). This follows the successful completion of Phase 1 trials for type 2 diabetes mellitus (T2DM), and the compound holds promise for use as both a standalone therapy and in combination treatments. Another significant asset, DA-1726, an innovative oxyntomodulin analogue that functions as a dual agonist for GLP-1 and glucagon receptors, is presently in preclinical development specifically for treating obesity. MetaVia's broader therapeutic pipeline also includes ANA001, a distinct oral niclosamide formulation intended for moderate COVID-19 patients; NB-01, designed to address painful diabetic neuropathy; NB-02, targeting cognitive impairment; and Gemcabene, for the management of dyslipidemia. The company engages in strategic partnerships, notably a licensing agreement with Pfizer Inc. for the research, development, manufacturing, and commercialization of Gemcabene. Additionally, a joint research collaboration with Dong-A ST and ImmunoForge supports the advancement of DA-1726. The entity adopted its current name, MetaVia Inc., in November 2024, transitioning from its former identity as NeuroBo Pharmaceuticals, Inc.
Prezzo delle azioni
$1.28
Capitalizzazione di mercato
$8.43M
Variazione (1 giorno)
4.07%
Variazione (1 anno)
-21.47%
Paese
US
Scambia MetaVia Inc. (MTVA)
Categoria
Healthcare
Rapporto P/B per MetaVia Inc. (MTVA)
Rapporto P/B al October 2026 TTM: 2.05K
Secondo gli ultimi rapporti finanziari e il prezzo delle azioni di MetaVia Inc., il rapporto P/B attuale (TTM) è 2.05K. Alla fine del 2023, era pari a 0.77.
Storico del rapporto P/B per MetaVia Inc. da 2014 a 2026
Rapporto P/B alla fine di ogni anno
| Anno | Rapporto P/B | Cambia |
|---|---|---|
| 2026 (TTM) | 2.05K | 9,295.93% |
| 2024 | 21.84 | 2,740.49% |
| 2023 | 0.77 | 1,955.88% |
| 2022 | 0.04 | 123.95% |
| 2021 | 0.02 | -29.54% |
| 2020 | 0.02 | 426.67% |
| 2019 | 0.00 | -1,225.00% |
| 2018 | 0.00 | -136.36% |
| 2017 | 0.00 | 450.00% |
| 2016 | 0.00 | -166.67% |
| 2015 | 0.00 | -95.89% |
| 2014 | -0.01 | 0.00% |
Rapporto P/B per aziende simili o concorrenti
| Azienda | Rapporto P/B | Differenza del rapporto P/B | Il paese |
|---|---|---|---|
| 6.251 | -99.70% |
US
|
|
| 13.2547 | -99.35% |
US
|
|
| 4.208 | -99.79% |
AU
|
|
| - | - |
CH
|
|
| 6.1824 | -99.70% |
NL
|
